NEW
Lusefi

Lusefi

Manufacturer:

Taisho Pharmaceutical

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Luseogliflozin hydrate
Indications/Uses
Monotherapy or add-on combination therapy w/ sulfonylurea or insulin prep in adult patients w/ type 2 DM.
Dosage/Direction for Use
2.5 mg once daily, may be increased to 5 mg once daily in order to achieve sufficient effect.
Administration
May be taken with or without food: Take before or after breakfast.
Contraindications
Hypersensitivity. Patients w/ severe ketosis, diabetic coma or pre-coma; severe infection, those who underwent or are scheduled for surgeries, w/ serious trauma.
Special Precautions
Discontinue use if ketoacidosis occur. Increased risk of hypoglycemia. Pituitary dysfunction or adrenal insufficiency; UTI, genital infection; diabetes-like symptoms eg, impaired glucose tolerance & positive urinary glucose; presence or absence of infections; hypovolemia; dysuria, anuria, oliguria or urinary retention. Poor nutritional status, starvation, irregular diet, insufficient dietary intake or debility; strenuous muscular exercise; excessive wt loss. Ensure adequate hydration during treatment. Periodically check plasma glucose, renal function & other parameters during treatment. Excessive alcohol consumption. Concomitant use w/ sulfonylureas, insulin prep, diuretics or GLP-1 receptor agonists. May affect ability to drive & use machines. Not recommended in moderate to severe renal impairment. Severe hepatic dysfunction. Not to be used in women of childbearing potential or during pregnancy. Avoid use during lactation. Childn <20 yr. Elderly.
Adverse Reactions
Cystitis; constipation; pollakiuria; increased blood ketone body & urine β2-microglobulin, positive WBC & albumin in urine.
Drug Interactions
Enhanced hypoglycemic action w/ antidiabetic drugs eg, sulfonylureas, biguanides, thiazolidinediones, DPP-4 & α-glucosidase inhibitors, glinides, GLP-1 receptor agonists, insulin prep; β-blockers, salicylic acids, MAOIs, fibrates. Weakened hypoglycemic action by adrenaline, corticosteroid, thyroid hormone. Enhanced diuretic action w/ loop & thiazide diuretics. Positive urinary glucose & decreased serum 1,5-anhydroglucitol.
MIMS Class
ATC Classification
A10BK07 - luseogliflozin ; Belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. Used in the treatment of diabetes.
Presentation/Packing
Form
Lusefi FC tab 2.5 mg
Packing/Price
100's
Form
Lusefi FC tab 5 mg
Packing/Price
100's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in